Page 354 - Read Online
P. 354
Page 12 of 12 Sharma et al. Neuroimmunol Neuroinflammation 2018;5:43 I http://dx.doi.org/10.20517/2347-8659.2018.51
33. Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, et al. Monocyte-derived IL-1 and IL-6 are differentially required for
cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med 2018;24:739-48.
34. Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, et al. T cells expressing CD19 chimeric antigen receptors for
acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015;385:517-28.
35. Bonifant CL, Jackson HJ, Brentjens RJ, Curran KJ. Toxicity and management in CAR T-cell therapy. Mol Ther Oncolytics
2016;3:16011.
36. Neelapu SS. An interim analysis of the ZUMA-1 study of KTE-C19 in refractory, aggressive non-Hodgkin lymphoma. Clin Adv
Hematol Oncol 2017;15:117-20.
